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Background: IL-31, a recently discovered member of the gp130/IL-6 cytokine family, is mainly expressed by human
mast cells and T helper type 2 cells. IL-31 is a key trigger of atopic dermatitis. Recent studies also suggest a role of
IL-31 in the pathogenesis of other allergic diseases including allergic rhinitis. In the present study we studied the
release of IL-31 and IL-13 in allergen-challenged allergic rhinitis patients.
Methods: Seven seasonal allergic volunteers underwent unilateral nasal provocation with allergen (and a control
challenge) with the disc method out of the allergy season. Nasal symptom scores (rhinorrhea, itching, sneezing,
obstruction) and bilateral nasal secretions were quantified before and after allergen provocation. IL-13 and IL-31 in
nasal secretions and serum were measured by electrochemiluminescent immunoassay or ELISA, respectively.
Results: Nasal allergen challenge induced the typical clinical symptoms and physiological changes. IL-31 and IL-13
in nasal secretions increased in four and five, respectively, volunteers at 5 h after allergen but not after control
challenge. We observed correlation trends between nasal IL-31 concentrations and IL-13 concentrations (r = 0.9,
p = 0.002), and IL-31 contents and symptom scores (r = 0.9, p = 0.013) 5 h after allergen provocation. No IL-31 could
be detected contralaterally or systemically in the sera.
Conclusions: The observed local upregulation of IL-31 mainly during the late phase reaction after nasal allergen
challenge suggests a role of IL-31 in allergic rhinitis. In which way IL-31 modulates the inflammatory reaction and
type 2 responses in allergic rhinitis remains to be investigated.
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IL-31 is a recently discovered member of the gp130/
IL-6 cytokine family, which includes IL-6, IL-11, IL-27,
oncostatin M (OSM), leukemia inhibitory factor (LIF),
ciliary neurotrophic factor, neuropoietin, cardiotrophin-1,
and cardiotrophin-like cytokine [1,2]. IL-31 signals
through a heterodimeric receptor composed of the IL-31
receptor alpha (IL-31RA) and the OSM receptor beta
(OSMR). IL-31RA has been identified as a gp130-like
receptor showing 28% homology to gp130, the com-
mon signalling receptor subunit of the family of IL-6-
type cytokines [3-5].* Correspondence: RalfB2@yahoo.com
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reproduction in any medium, provided the orIL-31 is expressed by human mast cells [6] and by
CD4+ T cells, particularly activated T helper type 2
(TH2) cells [1], and skin-homing CD45RO+ cutaneous
lymphocyte-associated antigen-positive T cells [7]. IL-31
receptors are expressed on a broad spectrum of immune
and non-immune cells including activated monocytes,
macrophages, eosinophils, basophils, dorsal root ganglia,
keratinocytes, and epithelial cells [2,8,9].
Several studies support a role for IL-31 in atopic
dermatitis and other epithelial pathologies. Mice treated
with intradermal injection of IL-31 or transgenic mice
overexpressing IL-31 presented increased scratching
behavior and developed severe dermatitis [1]. A neu-
tralizing anti-IL-31 monoclonal antibody ameliorated
scratching behavior in a mouse model of dermatitis
[10]. A common haplotype of the IL-31 gene was
characterized as a risk haplotype for nonatopicral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pressed in pruritic atopic dermatitis but not in psor-
iasis which is a mainly TH1-dependent inflammatory
disease, confirming an involvement of IL-31 in TH2-
mediated skin diseases [2]. In addition, IL-31 mRNA
expression was also increased in skin samples of
patients with allergic contact dermatitis and was cor-
related with IL-4 and IL-13 levels [12]. Increased
levels of IL-31 protein in serum and mRNA in per-
ipheral blood mononuclear cells (PBMCs) were found
in patients with allergic asthma [13]. Very recent evi-
dence showed pollen antigen-induced IL-31 protein
production from PBMCs in patients with allergic
rhinitis in association with the severity of allergic
rhinitis [14]. This IL-31 production was significantly
and positively correlated with the production of IL-5
and IL-13 [14].
IL-13, which is a central type 2 cytokine [15], and its
receptors have been shown to be produced by most im-
mune cells [5,16]. IL-13 is involved in B-cell maturation,
differentiation and IgE isotype switching. It down-
modulates macrophage activity, thereby inhibiting the
production of pro-inflammatory cytokines and chemo-
kines [5]. Many lines of evidence support an important
role of IL-13 in the pathophysiology of allergic asthma
and allergic rhinitis [17-20].
Allergic rhinitis is the most frequent allergic disease
and affects approximately 10% to 25% of the population
[21-23]. It invariably involves inflammation of the nasal
mucosa and often also the mucosa of other organs such
as eyes and sinuses [23,24]. To further elucidate the po-
tential role of IL-31 in allergic rhinitis, we studied the
release of IL-31 and IL-13 into nasal secretions and
serum after unilateral allergen challenge in seasonal al-
lergic volunteers. Nasal allergen provocation allows to
differentiate between the early and late phase of the al-
lergic reaction in the nose and to describe the time
course of release for cytokines and other mediators
[25,26]. We used the filter paper disc method which
allows the separate investigation of ipsi- and contralat-
eral effects after an unilateral allergen challenge [25,27].
Methods
Subjects
Eleven healthy, non-smoking subjects with seasonal al-
lergic rhinitis were included in the study. All subjects
provided a written informed consent and the study was
approved by the Ethics Committee of the Heinrich-
Heine University. The subjects were selected by means
of symptom history assessed by questionnaire and a skin
prick test showing sensitization for seasonal grass (grass
mix, Allergopharma Joachim Ganzer KG, Reinbek
Germany) or tree (tree II mix (birch, euopean beech,
plane, oak); Allergopharma) pollen allergens and negativeresults for common perennial allergens. The skin prick
test was performed according to the guidelines of the
German Society for Allergology and Clinical Immunology
[28]. In brief, after cleaning the skin with alcohol the posi-
tions of allergens were marked by numbered strips on the
volar sides of both forearms. A drop of each allergen was
applied to the corresponding spot of the skin. Saline
(negative control) and histamine dihydrochloride solution
(positive control) (Allergopharma) were included in the
test. The skin was gently pricked with a sterile lancet
(Allergopharma) through the drops using a perpendicular
motion. Between each prick the lancet was wiped on a
gauze to prevent contamination of the following site.
Eventually, the drops were blotted from the skin. The re-
action was read after 15 to 20 min and the presence of a
mean wheal diameter of at least 3 mm was regarded as a
positive [28-30]. In case of positive reactions to both grass
and tree pollen the allergen with the stronger reaction was
chosen for nasal provocation. Throughout the study the
subjects were out of allergy season to avoid natural aller-
gen exposition. None of the volunteers took any medica-
tion except oral contraceptives or showed evidence of
sinusitis or active rhinitis within months prior to challenge
or received specific immunotherapy with allergens in the
previous 3 years. Four subjects had to be excluded prior to
analysis because of procedural adverse events (nasal bleed-
ings; two excluded), incompliance (one excluded) or lack
of positive symptom scores after nasal allergen challenge
(one excluded). The remaining subjects were three men
and four women with an age range of 19–53 years and a
mean age of 31 years.
Localized nasal challenge
The allergen challenge and collection of nasal secretions
were carried out by a modified version of the filter disc
method [25]. Seventy-five μl of allergen solution (Aller-
gopharma) in a concentration of 50.000 BU/ml were
pipetted on a filter disc (10 mm diameter, 1.2 mm thick-
ness; Shandon filter cards; Shandon Inc., Pittsburgh, PA,
USA). Each challenge disc therefore contained 3.750 BU
of allergen. It was placed on the anterior portion of the
nasal septum for 1 minute. Ten minutes, two, five, and
24 hours after challenge nasal secretions were collected
by applying pre-weighed filter discs to the same spot of
the septum for 45 seconds in the ipsilateral nostril and
to the corresponding area of the contralateral nasal
septum.
Symptoms were quantified by visual analog scales for
secretion, obstruction and itching. Sneezes were counted
and the nasal air flow was evaluated by anterior rhino-
manometry (Atmos Rhinomanometer 300; ATMOS
MedizinTechnik; Lenzkirch, Germany) at all measure-
ment points. Prior to the challenge anatomic anomalies
were ruled out by anterior rhinoscopy. To wash out
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secretions, five consecutive nasal lavages were performed
with 0.9% isotonic sodium chloride solution (B. Braun
Melsungen A.G., Melsungen, Germany).
To determine potential unspecific reactions, a disc
challenge with diluent alone (sterile saline; Allergo-
pharma) was performed prior to the allergen challenge.
Furthermore, control challenges using the diluent alone
were performed (analog to the allergen challenge proto-
col) either at least four days before or at least two weeks
after the allergen challenge.
After collection each filter disc were weighed, placed
in a 2 ml Cryo S PP round bottom tube (Greiner Bio-
One, Frickenhausen, Germany) and eluted in 500 μl of
0.9% sodium chloride solution for approximately 3 h
while gently shaking at 4°C. After removal of the disk,
the eluate was centrifuged at 2800 rpm (Biofuge 15R;
Heraeus Instruments; Duesseldorf, Germany) to remove
mucus and cell material. The supernatant was aliquoted
into 0.5 ml tubes (LoBind; Eppendorf AG; Hamburg,
Germany) and stored at −80°C until analysis.
Serum
Five ml of peripheral blood were collected using SST II
tubes (Becton, Dickinson and Company (BD), Heidel-
berg, Germany) from all participants before and 5 and
24 h after nasal allergen challenge. After clotting of the
blood, serum was separated by centrifugation at 4°C and
stored in aliquots at −80°C.
IL-31 enzyme-linked immunosorbent assay
IL-31 levels in nasal secretions and in serum were ana-
lyzed using a commercially available pre-coated enzyme-
linked-immunosorbent-assay (ELISA) (LEGEND MAX™
Human IL-31 ELISA Kit; BioLegend, Inc.; San Diego,
CA, USA) with a sensitivity of <7.3 pg/ml. The IL-31
ELISA was performed according to the manufacturer’s
instructions and the ELISA-plates were read on an Elisa
Reader (DTX 880 Multimode Detector, Beckmann
Coulter GmbH, Krefeld, Germany). Duplicate concentra-
tion values were ≤20%. The concentrations and contents
of nasal IL-31 were calculated considering the amount
of generated nasal secretions.
Electrochemiluminescent IL-13 Immunoassay
IL-13 levels in nasal secretion samples were analyzed
using a commercially available ultrasensitive pre-coated
electrochemiluminescence immunoassay (Human IL-13
Ultra-Sensitive Kit; Meso Scale Discovery (MSD),
Gaithersburg, MD, USA) with a sensitivity of <6.9 pg/
ml. The IL-13 standard was diluted either in isotonic So-
dium Chloride Solution/1% Blocker A (MSD) or Diluent
2 (MSD) for the investigation of nasal secretions or
serum, respectively. All incubations of the immunoassaywere done sealed on an orbital shaker (Eppendorf ) at
room temperature. Plates were blocked with 25 μl Dilu-
ent 2 (MSD) for 30 min, before 25 μl of zero standards
in triplicates and of standards and samples in duplicates
were added. After 2 ½ h of incubation and three washes,
twenty-five μl of anti-IL-13 antibody labelled with Sulfo-
Tag (MSD) were added to each well and incubated for
additional 2 h protected from light. After further four
washes, 150 μl of 2x read buffer (MSD) were added per
well and the plate was immediately read on the Sector
Imager 6000 (MSD). Raw data were analyzed using the
Discovery Workbench 3.0 software (MSD). The concen-
trations and total amounts of nasal IL-13 were calcu-
lated considering the amount of generated nasal
secretions.
Statistics
Because the data were not normally distributed, non-
parametric statistics were employed. Statistical analyses
were performed using Medcalc software 12.1.0 (Kagi,
Berkeley, CA). Graphics were done using GraphPad
Prism (GraphPad, San Diego, CA, USA). To examine
differences between points on either the diluent or the
allergen challenge curves, Friedman analysis of variance
(ANOVA) was used. If a significant overall difference
was found, post-hoc analysis was performed using the
method given by Conover [31] to identify time points
showing significantly different levels compared to the
baseline and diluent time points. Correction for mul-
tiple testing has not been applied. Correlations were
evaluated by the Spearman rank test and Kendall´s tau
test. P < 0.05 (two-tailed) was considered statistically
significant. If not otherwise stated mean ± SEM is
displayed.
Results
Following nasal allergen challenge, nasal symptoms and
cytokine levels increased significantly (Figures 1 and 2).
Postallergen symptom score (mean of itching, obstruc-
tion and secretion score) was elevated rapidly within
10 min [diluent: 2.3 ± 1.3 mm; allergen (10 min):
53 ± 8 mm] and gradually abated during the following
24 h, remaining significantly elevated until 5 h after al-
lergen challenge [24.7 ± 7.5 mm] (Figure 1A). In con-
trast, control challenge with the diluent alone did not
cause any statistically significant changes (Figure 1A).
The number of sneezes was significantly increased in the
minutes after the allergen challenge [diluent: 0 ± 0; aller-
gen (10 min): 5.4 ± 3.2] returning soon to low levels and
zero thereafter (Figure 1B). Nasal flow measured by rhi-
nomanometry decreased from 280 ± 64 cm3/s (diluent)
to 115 ± 51 cm3/s 10 min after allergen challenge and
gradually returned to the original level until the 24 h
































































































Figure 1 Time course of symptoms and nasal airway flow after unilateral nasal allergen challenge. Symptom scores (A) and sneezes (B)
and ipsilateral (C) or contralateral (D) nasal airway flow after unilateral nasal allergen challenge are shown. Nasal air flow was evaluated by
anterior rhinomanometry. Nasal symptoms and airway flow were evaluated before and at all time-points following allergen challenge. The
dashed line represents values obtained after control challenge on a separate day using the same protocol. Values presented are means ± SEM
(n = 7; *p < 0.05).
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http://www.ctajournal.com/content/2/1/13On the contralateral side its drop immediately after the
allergen provocation was less pronounced from




































Figure 2 Time course of IL-13 and IL-31 in ipsilateral nasal secretions
(C, D) concentrations (A, C) and contents (B, D) in ipsilateral nasal secretion
time-points following allergen challenge. The dashed line represents values
protocol. Values presented are means ± SEM (n = 7; *p < 0.05).IL-13 was found in very low amounts in nasal secre-
tions before and 10 min after nasal provocation, but


































after unilateral nasal allergen challenge. The IL-13 (A, B) and IL-31
s are shown. Nasal secretions were collected before and at all
obtained after control challenge on a separate day using the same
Table 2 Associations between nasal cytokine contents
and symptoms (n = 7)
IL-13 at 5 h IL-31 at 5 h
rho* (p) tau** (p) rho* (p) tau** (p)
Symptom
scores at 5 h
0.94 (0.002) 0.85 (0.012) 0.86 (0.013) 0.74 (0.031)
Obstruction
at 5 h
0.85 (0.016) 0.68 (0.045) 0.85 (0.015) 0.72 (0.035)
IL-13 at 5 h - 0.82 (0.023) 0.63 (0.068)
* Spearman correlation analysis.
** Kendall correlation analysis.
Non-significant correlations are in italic.
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2482 ± 1629 pg/ml; content 141 ± 108.9 pg] before falling
again to low levels after 24 h (Figure 2A and B; Friedman
ANOVA: p = 0.006 (A), p = 0.031 (B)). In one of the seven
subjects, IL-13 was only detectable after 24 h. On
the contralateral side, IL-13 levels remained very low
(data not shown). No statistically significant changes
for IL-13 concentration and content were observed
after control challenge with the diluent alone
(Figure 2A and B).
Generally, IL-31 was below the limit of detection of
the assay in nasal secretions before nasal provocation. In
four of the seven allergic volunteers nasal IL-31 was still
undetectable at the early response but increased 5 h
after provocation on the ipsilateral side [concentration
786 ± 522 pg/ml; content 44 ± 35.4 pg] before falling
again to undetectable levels after 24 h (Figure 2C and D;
Friedman ANOVA: p < 0.001 (C, D)). In a fifth subject a
low nasal IL-31 level was detected exclusively at the
10 min time point. In the remaining two subjects, no
nasal IL-31 was detected at any measuring time point
after nasal provocation. On the contralateral side, no IL-
31 was measured (data not shown). No IL-31 could be
detected after control challenge (Figure 2C and D).
Nasal concentrations and contents of IL-31 and IL-13
at 5 h were tested for correlations to each other as well
as to symptom scores at 5 h (Tables 1 and 2). Due to the
low number of study participants and some zero values
of IL-31 and IL-13 levels at 5 h, Kendall´s tau test was
performed besides the Spearman rank test (Tables 1 and 2).
For the same reason, we speak of correlation trends instead
of correlations also in case of significant p-values. In
Figure 3, only those association trends with significant
p-values according to the Kendall´s tau test are depicted.
Nasal IL-13 concentrations and contents showed correl-
ation trends with nasal symptom scores (concentration:
Spearman rank test: r = 0.86, p=0.012; Kendall’s tau test:
tau=0.75, p= 0.027; content: r = 0.94, p= 0.002; tau=0.85,
p=0.012) (Figure 3A and B; Table 1 and 2). There was a
correlation trend between symptom scores with IL-31Table 1 Associations between nasal cytokine
concentrations and symptoms (n= 7)
IL-13 at 5 h IL-31 at 5 h
rho* (p) tau** (p) rho* (p) tau** (p)
Symptom
scores at 5 h
0.86 (0.012) 0.75 (0.027) 0.82 (0.023) 0.63 (0.067)
Obstruction
at 5 h
0.77 (0.041) 0.59 (0.091) 0.82 (0.025) 0.62 (0.074)
IL-13 at 5 h - 0.94 (0.002) 0.84 (0.013)
* Spearman correlation analysis.
** Kendall correlation analysis.
Non-significant correlations are in italic.contents (r =0.86, p=0.013; tau=0.74, p=0.031)
(Figure 3E; Table 2). IL-31 showed an association trend
with IL-13 concentrations (r =0.94, p=0.002; tau=0.84,
p=0.013) (Figure 3D; Table 1). When we compared nasal
itching, obstruction, and secretion at 5 h with nasal concen-
trations and contents of IL-31 and IL-13 at 5 h using Ken-
dall´s tau test (Tables 1 and 2), we found an association
trend for obstruction at 5 h with both IL-31 and IL-13 con-
tents (tau=0.72, p=0.035 and tau=0.68, p=0.045, respect-
ively) (Figure 3C and F; Table 2).
As far as detectable, both IL-31 and IL-13 serum levels
did not change 5 and 24 h after nasal allergen challenge
compared to baseline (data not shown). IL-31 serum
levels were only detectable in the subject who showed a
low nasal IL-31 level already 10 min after nasal allergen
challenge.
Discussion
Our study demonstrates for the first time that IL-31 is
released into nasal secretions after nasal pollen allergen
challenge in patients with allergic rhinitis. The first indi-
cation for a role of IL-31 in allergic rhinitis was provided
by the characterization of in vitro IL-31 production in
pollen antigen–induced PBMC responses in patients
with allergic rhinitis [14].
Okano and collegues reported that around two thirds
of these PBMCs produced detectable amounts of IL-31
in response to pollen allergens in vitro in association
with the severity of allergic rhinitis [14]. We observed
nasal IL-31 at detectable levels in five of seven allergic
rhinitis patients, four of these peaked at 5 h after nasal
provocation. Furthermore, we also found IL-31 contents
to show correlation trends to symptoms and thus the se-
verity of allergic rhinitis, suggesting that IL-31 produc-
tion might lead to a deterioration in the pathophysiology
of allergic rhinitis. Due to the limited number of partici-
pants with detectable local cytokine levels (and hence
some zero values) after nasal allergen challenge we sug-
gest to speak of correlation trends even in case of signifi-
cant p-values. Our finding that local IL-31 levels did not
correlate with itching after a single nasal allergen
























































































Figure 3 Correlation trends of cytokine levels with nasal symptom scores and each other. A, B and E: Symptom scores with IL-13
concentrations (A), IL-13 contents (B) and IL-31 contents (E); C, F: Obstruction with IL-13 contents (C) and IL-31 contents (F); D: IL-13 and IL-31
concentrations. Nasal symptoms were calculated as the mean of secretion, obstruction and itching (visual analog scale (VAS)). The corresponding
correlation coefficients and p-values calculated by the Spearman rank test as well as the Kendall´s tau test are depicted in Tables 1 and 2 (n = 7).
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previously described link between IL-31 and itching in
atopic skin disease [1,10] and may suggest other func-
tions of IL-31 in allergic rhinitis.
Generally, accumulating evidence supports a patho-
physiological role of IL-31 in atopic dermatitis and
other allergic diseases [1,2,10,11], however its exact
mechanisms have not been finally resolved yet
[5,8,32,33]. IL-31 may enhance skin inflammation
through the induction of several chemokine genes such
as CCL17, CCL22 and CCL1 in human keratinocytes
[1] which subsequently leads to the recruitment of T-
cells, and in turn may become new sources of IL-31 [2].
IL-31 can induce cytokine and chemokine production
from human bronchial epithelial cells [9] and eosino-
phils [34]. Similar pathophysiological mechanisms might
also play a pivotal role in the late phase of nasal inflam-
mation of allergic rhinitis, given the influx of inflamma-
tory cells such as eosinophils, basophils, T- and B-cells
into the mucosa and potential interactions with resident
epithelial cells [35-38].
IL-13 regulates inflammatory and type 2 immune
responses [15]. It shares many similarities with IL-4, as
both cytokines use IL-4Ralpha as receptor subunit
[16,39]. In allergic rhinitis, IL-13 is expressed in the
nasal mucosa of patients with perennial allergic rhinitis
and after allergen provocation [18,19,40]. In nasal secre-
tions of patients with seasonal allergic rhinitis, IL-13
appeared between 4 and 8 h and peaked 6 h after nasal
allergen challenge [19]. We included the type 2 cytokineIL-13 in our study because IL-31 mRNA expression in
skin samples of patients with atopic dermatitis or allergic
contact dermatitis was reported to be correlated with
IL-13 levels [12]. Furthermore, allergen-induced IL-31
protein production by PBMCs in patients with allergic
rhinitis was significantly and positively correlated with
the production of IL-13 [14]. Our results confirm previ-
ous findings describing an involvement of IL-13 in nasal
late-phase response in allergic rhinitis [18,19]. Further-
more, our finding of a correlation trend between nasal
IL-31 and IL-13 concentrations in the late phase of the
allergic reaction following a single nasal allergen chal-
lenge may imply that one cytokine induces the other or,
alternatively, may point to a common mechanism of
induction.
In a mouse model of allergic rhinitis, an essential con-
tribution of IL-13 to the late-phase response in allergic
rhinitis was shown by means of either IL-13−/− (knock-
out) mice or a soluble IL-13 inhibitor [20]. Therapeutical
interventions in allergic diseases such as allergen-
induced asthma specifically targeting IL-4, IL-5 or IL-13
cytokines caused none to moderate improvement
regarding disease severity and symptoms [41]. This sug-
gests a partial redundancy of these cytokines and/or
contributions of other mediators to this disease. Indeed,
administration of mutant IL-4 protein that inhibits the
binding of IL-4 and IL-13 to IL-4R complexes, has re-
cently shown efficacy in the treatment of allergen-
induced asthma [42]. If IL-31 is an interesting candidate
for therapeutical interventions in allergic rhinitis
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investigated by inhibition of IL-31 via antibodies [10] or
specific inhibitors [43].
The limitations of our study such as the small number
of volunteers and the relatively small number of time-
points could be overcome in future studies. Neverthe-
less, more detailed investigations of the timecourse
should also include more sensitive IL-31 protein detec-
tion methods. Moreover, healthy control subjects under-
going nasal allergen challenge could be included in
future studies. Additionally, functional assays to explore
the roles of IL-31 on the cellular influx and its effects on
resident cells in allergic rhinitis should be considered.
Conclusions
We demonstrated the release of IL-31 into ipsilateral
nasal secretions after unilateral nasal allergen challenge
in patients with allergic rhinitis. We found a correlation
trend of IL-31 contents with the severity of allergic rhin-
itis. Furthermore, we confirmed previous reports about
the increase of IL-13 in nasal secretions particularly in
the late-phase response in allergic rhinitis. The concen-
trations of this central type 2 cytokine showed a correl-
ation trend to IL-31 following a single nasal allergen
challenge. These findings suggest that IL-31 exerts a
pathophysiological role in allergic rhinitis.
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